CVS Health: Rapidly Improving Metrics And Promising Recovery Deserve Reiterated Buy Rating

The +2.48% YoY payment hike for 2027 Medicare Advantage plans and Aetna's higher star rating support CVS Health's recovery prospects toward 2028 target margins. This is significantly aided by the prior premium re-pricing and the ongoing operational efficiencies, as observed in their FQ1 '26 MBR of 84.6% nearing 2019 levels. Readers must not forget their vertically integrated PBM and pharmacy capabilities, allowing them to drive lower medical costs and improved operational efficiencies.